Metrics as of 10/13/2026, 06:36 PM (Berlin time), refresh in progress.
Resverlogix Stock
Resverlogix Corp.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- Donald J. McCaffrey
- Employees
- 17
- Market cap
- $29 M
- IPO
- 07/05/2004
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit…
Resverlogix stock: price history
1D
+0.0%
1W
+0.0%
1M
-5.6%
6M
-19.0%
YTD
-15.0%
1Y
-22.7%
2Y
+30.8%
5Y
-83.7%
10Y
-95.9%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~10% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Resverlogix
Resverlogix stock metrics
P/E
-1.73
P/B
-0.21
EV/EBITDA
-27.27
RETURN ON EQUITY
6.3%
NET MARGIN
0.0%
DEBT/EQUITY
-0.82
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
67.2%
FLOAT SHARES
231,184,425
AVG. DAILY VOLUME (30D)
30,838
Comparable stocks
Frequently asked questions about Resverlogix stock
What does Resverlogix do?
Resverlogix Corp. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is Donald J. McCaffrey, the company employs around 17 people.
The IPO was on 07/05/2004; the stock trades on TSX under the ticker RVX.TO.
When does Resverlogix report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -10% stronger than usual.
Does Resverlogix pay a dividend?
No, Resverlogix currently does not pay a dividend.
Which stocks are comparable to Resverlogix?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Resverlogix stock analyzed?
Clicking "Analyze stock" lets five strategies assess Resverlogix against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.